Agenus Inc. (NASDAQ:AGEN - Free Report) - HC Wainwright raised their Q4 2024 earnings per share (EPS) estimates for Agenus in a report issued on Thursday, December 5th. HC Wainwright analyst E. Bodnar now expects that the biotechnology company will post earnings of ($2.62) per share for the quarter, up from their previous estimate of ($2.88). HC Wainwright currently has a "Neutral" rating on the stock. The consensus estimate for Agenus' current full-year earnings is ($12.93) per share. HC Wainwright also issued estimates for Agenus' Q4 2025 earnings at ($1.26) EPS, FY2025 earnings at ($6.85) EPS, FY2026 earnings at ($6.04) EPS, FY2027 earnings at ($6.45) EPS and FY2028 earnings at ($6.70) EPS.
Several other research firms have also recently commented on AGEN. StockNews.com cut Agenus from a "hold" rating to a "sell" rating in a research note on Monday, August 12th. B. Riley lowered their price objective on Agenus from $42.00 to $18.00 and set a "buy" rating for the company in a report on Wednesday, August 14th. One analyst has rated the stock with a sell rating, five have given a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat.com, Agenus presently has an average rating of "Hold" and a consensus price target of $10.00.
Check Out Our Latest Stock Report on AGEN
Agenus Trading Down 2.2 %
Shares of NASDAQ:AGEN traded down $0.08 during trading on Monday, hitting $3.50. The company's stock had a trading volume of 415,834 shares, compared to its average volume of 649,255. Agenus has a fifty-two week low of $2.50 and a fifty-two week high of $19.69. The stock's 50-day moving average price is $3.98 and its two-hundred day moving average price is $7.78.
Hedge Funds Weigh In On Agenus
Several institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. grew its holdings in Agenus by 13.7% in the 1st quarter. Vanguard Group Inc. now owns 34,401,122 shares of the biotechnology company's stock worth $19,953,000 after buying an additional 4,134,232 shares in the last quarter. Walleye Capital LLC acquired a new stake in Agenus in the third quarter worth approximately $1,003,000. Price T Rowe Associates Inc. MD lifted its position in Agenus by 52.4% in the first quarter. Price T Rowe Associates Inc. MD now owns 357,915 shares of the biotechnology company's stock worth $208,000 after purchasing an additional 123,058 shares during the period. Federated Hermes Inc. acquired a new stake in Agenus in the second quarter worth approximately $1,921,000. Finally, Susquehanna Fundamental Investments LLC acquired a new stake in Agenus in the second quarter worth approximately $1,050,000. 61.46% of the stock is owned by institutional investors.
About Agenus
(
Get Free Report)
Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.
Further Reading
Before you consider Agenus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agenus wasn't on the list.
While Agenus currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
